Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Seasonal Influenza

Seasonal Influenza

Part of Orthomyxoviridae Infections

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Seasonal Influenza

14 trials tracked for Seasonal Influenza: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 61 citations.

14Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 5 Phase 2 7 Phase 1 1
  1. Phase 3 Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Completed · 61 cited
  2. Phase 4 Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Completed
  3. Phase 3 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Completed
  4. Phase 3 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Completed
  5. Phase 3 Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age Completed
  6. Phase 3 Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Completed
Show 8 more trials
  1. Phase 2 A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Completed
  2. Phase 2 Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Completed
  3. Phase 2 A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults Completed
  4. Phase 2 A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults Completed
  5. Phase 2 Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010 Completed
  6. Phase 2 Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011 Completed
  7. Phase 2 Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 Completed
  8. Phase 1 First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Seasonal Influenza: what the trials found

Several established trials evaluated the immunogenicity and efficacy of mRNA-1010, a seasonal influenza vaccine. In a phase 3 trial (N=8411), mRNA-1010 induced seroconversion rates ranging from 34.9% to 64.4% across strains, with 92.0% to 96.7% of participants achieving HAI titers ≥1:40 2. Another large phase 3 trial (N=22502) reported seroconversion rates of 29.4% to 52.0% and HAI titers ≥1:40 in 85.5% to 94.8% of participants 3. A third phase 3 trial (N=6102) showed seroconversion rates of 32.4% to 80.1% and HAI titers ≥1:40 in 80.7% to 97.6% 4. However, in the efficacy analysis, mRNA-1010 did not significantly reduce the first episode of RT-PCR-confirmed influenza-like illness (ILI) caused by any seasonal influenza strain (142 vs 140 events; p=0.1715) 3. In a phase 1/2 trial (N=885), seroconversion rates with mRNA-1010 ranged from 4.9% to 90.2% depending on dose and strain 9.

A cell-derived influenza vaccine (cTIV) was compared to traditional TIV in a phase 4 trial (N=1398). Among subjects with underlying medical conditions, the percentages achieving HAI titers ≥40 after one vaccination ranged from 40% to 98% for cTIV and TIV, with seroconversion rates of 56% to 72% 1. A phase 3 trial (N=3116) of TIV reported seroconversion rates of 78% to 95% and HAI titers ≥40 in 48% to 97% of subjects 6. For the antiviral peramivir, a phase 3 trial (N=234) showed a change from baseline in influenza virus titer at 48 hours of -1.66 vs -1.47 5.

Recent results — preliminary, needs further review

  • A phase 2 trial (N=698) of mRNA-1011.1 reported geometric mean fold rises (GMFR) of anti-HA antibodies at day 29 ranging from 2.7 to 3.7 across strains, with seroconversion rates of 35.9% to 49.4% 7.
  • Another phase 2 trial (N=572) of mRNA-1030 showed GMFRs of 5.29 to 9.93 and seroconversion rates of 56.7% to 75.4% 8.
  • Several small phase 2 trials (N=63-84) evaluated MF59-adjuvanted subunit influenza vaccines. One trial (N=84) reported seroconversion rates of 53% to 100% and HI titers >1:40 in 57% to 100% 10. Three other trials (N=63-64) using FLUAD showed seroconversion or significant increase in SRH area ranging from 26% to 69% 11, 43% to 46% 12, and 27% to 61% 13.
  • A phase 1 trial (N=63) of an Adjuplex-adjuvanted vaccine (VRC-GENADJ0110-AP-NV) reported local and systemic reactogenicity within 7 days, with 0-12 participants reporting local symptoms and 1-13 reporting systemic symptoms across dose groups 14.

For the clinician treating this condition

  • mRNA-1010 induces robust antibody responses (seroconversion and HAI titers ≥1:40) across multiple phase 3 trials, but did not demonstrate significant efficacy against RT-PCR-confirmed ILI in one large trial 234.
  • Cell-derived and traditional TIV vaccines show comparable immunogenicity in subjects with underlying medical conditions and in general populations 16.
  • Peramivir reduces influenza virus titers at 48 hours compared to baseline 5.

AI synthesis of 14 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
mRNA-1010 shows superior efficacy against influenza in older adults
Drug Pipeline RCT
mRNA-1010 shows superior efficacy against influenza in older adults New flu shot cuts illness by 27 percent in adults over 50
A phase 3 trial found mRNA-1010 vaccine had 26.6% relative efficacy versus standard comparator in adults 50+.
A new mRNA flu vaccine reduced confirmed flu illness by 27 percent compared with the standard shot in adults 50 and older.
May 7, 2026
Coadministration of RSV mRNA vaccine and high-dose flu vaccine noninferior for flu but not for RSV in older adults
Drug Pipeline RCT
Coadministration of RSV mRNA vaccine and high-dose flu vaccine noninferior for flu but not for RSV in older adults New data shows RSV and flu shots work well together
This phase 3 randomized controlled trial in 1900 adults aged 65 and older compared coadministration of mRNA-1345 and quadrivalent influenza …
Older adults can now get their RSV and flu vaccines during one visit without safety risks or extra trips to the clinic for care.
Apr 29, 2026
ACIP Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines
Allergy & Immunology
ACIP Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines What's the latest advice on flu shots this season?
The Advisory Committee on Immunization Practices (ACIP) has published recommendations for the prevention and control of seasonal influenza u…
U.S. health officials released updated flu shot advice for the 2023-24 season, emphasizing vaccination as the core way to prevent and contro…
CDC Apr 4, 2026
ACIP Issues Recommendations for Seasonal Influenza Vaccine Use in 2022-23
Allergy & Immunology
ACIP Issues Recommendations for Seasonal Influenza Vaccine Use in 2022-23 What flu shot should you get this year? Here are the official recommendations
The Advisory Committee on Immunization Practices (ACIP) has published its annual recommendations for seasonal influenza vaccine use in the U…
The 2022-23 flu season has official vaccine recommendations from experts to help you get the best protection against circulating strains.
CDC Apr 4, 2026
CDC Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines
Allergy & Immunology
CDC Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines Health officials release updated recommendations for seasonal flu vaccines
The CDC has published recommendations and reports for the prevention and control of seasonal influenza with vaccines in the United States.
CDC releases updated flu vaccine guidance for the upcoming season, advising doctors and the public on who should get vaccinated and when.
CDC Apr 3, 2026

Research across Orthomyxoviridae Infections

Related studies from across the Orthomyxoviridae Infections family.

Toll-like receptor signaling governs inflammatory phenotypes and progression in infectious myocarditis
Cardiology Sys. Review
Toll-like receptor signaling governs inflammatory phenotypes and progression in infectious myocarditis Toll-like receptors shape severity of infectious myocarditis
This systematic review examines the role of toll-like receptors (TLRs) in infectious myocarditis associated with COVID-19, influenza, and se…
A systematic review finds that pathogen-specific TLR signaling determines inflammation and outcomes in infectious myocarditis, with COVID-19…
Frontiers Jul 15, 2026
Respiratory viral coinfections reshape immune signaling and granuloma stability in Mycobacterium tuberculosis infections
Nephrology Sys. Review
Respiratory viral coinfections reshape immune signaling and granuloma stability in Mycobacterium tuberculosis infections Viral Infections May Change How the Body Fights Tuberculosis
This narrative review synthesizes how respiratory viruses, including SARS-CoV-2 and influenza, impact host immune signaling and granuloma eq…
Research shows that common respiratory viruses like flu or COVID-19 can change how the immune system responds to tuberculosis infections.
Frontiers Jul 4, 2026
Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu
Infectious Disease Meta-analysis
Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu Healthcare students often lack clear knowledge on antibiotics and viruses
This meta-analysis of 131 studies from 43 countries found that while 88.7% of healthcare students correctly knew antibiotics treat bacterial…
Many healthcare students are unsure if antibiotics can treat common colds or flu, which may lead to improper use of these important medicine…
Jul 3, 2026
TCM influenza research surges after 2020, shifting from clinical practice to mechanistic studies
Rheumatology Sys. Review
TCM influenza research surges after 2020, shifting from clinical practice to mechanistic studies Traditional Chinese Medicine Research on Influenza Surges After 2020
A systematic bibliometric analysis of 1,527 publications maps the landscape of Traditional Chinese Medicine (TCM) research on influenza. The…
A review of 1,527 publications shows TCM research for influenza has grown rapidly since 2014, with a sharp rise after 2020. China leads in o…
Frontiers Jun 23, 2026
Synergistic Effects of Prior Influenza and COVID-19 Vaccination on Future Vaccine Uptake
Primary Care & Family Medicine Meta-analysis
Synergistic Effects of Prior Influenza and COVID-19 Vaccination on Future Vaccine Uptake Prior Flu Vaccines May Increase Willingness to Get COVID Shots
Meta-analysis data suggests that prior experience with influenza vaccines significantly boosts patient willingness to receive COVID-19 vacci…
People who have received flu vaccines in the past show a higher willingness and likelihood to get vaccinated against COVID-19.
Frontiers Jun 17, 2026
High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months
Pediatrics RCT
High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months High-dose flu shots show greater protection for young children in China
This randomized, double-blind study in 3,000 Chinese children aged 6 to 35 months found an investigational high-dose quadrivalent influenza …
A new study in China shows high-dose flu vaccines work as well as or better than standard shots for toddlers, offering stronger protection a…
May 28, 2026
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years
Pediatrics RCT
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years Higher adjuvant content boosts immunity in children without added safety risks
This phase 2, observer-blind, multicenter study evaluated six formulations of MF59-adjuvanted H5N1 vaccine in 420 healthy infants and childr…
A Phase 2 trial in healthy children found that higher adjuvant content improved immune responses to an H5N1 vaccine without increasing side …
Apr 30, 2026
Systematic review and meta-analysis finds bacterial co-infection in 17.3% of hospitalized influenza patients
Infectious Disease
Systematic review and meta-analysis finds bacterial co-infection in 17.3% of hospitalized influenza patients Hospital data shows high rates of bacterial co-infection in influenza patients
This systematic review and meta-analysis of 111,889 hospital-attended patients with laboratory-confirmed influenza found a pooled prevalence…
Analysis of over 111,000 patients reveals that bacterial co-infection occurs in 17.3% of hospital cases with confirmed influenza infection.
medRxiv Apr 30, 2026
Survey finds physicians show stronger intergroup bias than public on vaccines
Infectious Disease
Survey finds physicians show stronger intergroup bias than public on vaccines Doctors Show Strong Bias Against Vaccine-Hesitant Patients
This review of an online survey in Japan involving 492 physicians and 5,252 members of the general public found that physicians exhibited hi…
Doctors often see themselves as targets of vaccine anger, but new data shows they also hold strong bias against patients who question vaccin…
medRxiv Apr 26, 2026
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions
Drug Pipeline Meta-analysis
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions Ancient Herbs May Help Modern Health
This systematic review synthesizes data on Rhaponticum species, covering 24 documented species worldwide and their applications for conditio…
Imagine walking through a garden filled with wildflowers.
Frontiers Apr 24, 2026
Infection status associated with hypoxemia and death rates varying by virus type in a large US cohort
Geriatrics & Aging Cohort
Infection status associated with hypoxemia and death rates varying by virus type in a large US cohort Triple Virus Infections Rarer Than Feared — Here’s the Real Risk
This cohort study of 835,987 triple-tested patients in the US Veterans Health Administration examined associations between infection status …
It’s winter. Your throat is scratchy. Your chest feels tight.
Frontiers Apr 23, 2026
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens
Infectious Disease Sys. Review
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens New Vaccine Map Helps Pick Best Tools
This narrative review examines virus-like particle (VLP) engineering strategies, including genetic fusion, modular conjugation, and nucleic …
Imagine trying to fix a leaky roof with every tool in the shed.
Frontiers Apr 23, 2026

Questions about Seasonal Influenza

Can I get the RSV and seasonal influenza vaccines at the same time?

Yes, you can get the RSV and seasonal influenza vaccines at the same time. Research shows this is safe and does not reduce the effectiveness of the flu shot.

Full answer →